Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 convalescent plasma (University Hospital, Geneva)
- Development stage
- Unknown
- Lead developer
- University Hospital
- Administration
- Intravenous
01
Overview
SARS-CoV-2 convalescent plasma is a passive immunotherapy derived from the blood of individuals who have recovered from COVID-19. This plasma contains high titers of neutralizing antibodies (nAbs) specifically targeting the SARS-CoV-2 virus. Developed and studied by the University Hospital, Geneva (HUG), this treatment is intended for early administration in high-risk groups, such as immunocompromised patients and the elderly, to prevent the progression of COVID-19 to severe stages. The mechanism involves the direct neutralization of viral particles, thereby reducing viral load and limiting tissue damage. In the Geneva-led multicentric trial, the plasma used is required to have a neutralizing antibody titer of at least 1:160.
- Other names
- SARS-CoV-2 convalescent plasmaSARS-CoV2 convalescent plasmaSARS-CoV 2 convalescent plasmaCOVID-19 convalescent plasmaCOVID19 convalescent plasmaCOVID 19 convalescent plasma
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SARS-CoV-2 convalescent plasma (University Hospital, Geneva).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 convalescent plasma (University Hospital, Geneva).